The company went public on June 30, 2022. The company has been selected as a G20 enterprise in the Beijing Pharmaceutical Industry Leapfrog Development Project, ranked among the top 100 chemical drug research and development capabilities in China, and has been widely recognized within and outside the industry. The company is mainly engaged in R&D, production and sales of pharmaceutical preparations and medical devices. The main products are compound α-ketoacid tablets, olmesartan ester tablets, trimetazidine hydrochloride tablets, losartan potassium hydrochlorothiazide tablets, moxifloxacin hydrochloride tablets, pivermonium bromide tablets, piveronium bromide tablets, acarbose tablets, paroxetine hydrochloride tablets, venlafaxine hydrochloride sustained-release capsules, atorvastatin calcium tablets, piverbium bromide tablets, caserol, reglinide tablets, acarbose tablets Tine tablets, venlafaxine hydrochloride extended-release capsules, etc. Company Honors: Beijing Biomedical Industry Leapfrogging Development Project (G20) - industry leading enterprise, high-tech enterprise.